Kyverna Therapeutics, Inc. (KYTX) — Stock Score Summary

Kyverna Therapeutics, Inc. (KYTX) has a MoatMap StockRank of 25/100 based on Quality (28/100), Value (37/100), and Momentum (47/100) factor scores. The current signal is SELL. Kyverna is a clinical-stage cell therapy biotech. It is highly dependent on specialized CDMOs for complex CAR-T manufacturing, making it a direct casualty of the CDMO pricing power cycle.

Kyverna Therapeutics, Inc. is a clinical-stage biotechnology company developing cell therapies for serious autoimmune diseases. The company's lead candidate, KYV-101, is an autologous CD19-targeting CAR T-cell therapy in development for B-cell driven autoimmune conditions. Kyverna's innovative approach aims to address significant unmet needs in chronic autoimmune disorders, leveraging advanced cell therapy technology.

Key Financial Metrics

Price$7.85
Market Cap$526M
P/E (Forward)-2.69
Price/Book2.46
Return on Equity-74.5%
Return on Invested Capital-62.5%
Debt/Equity17.26
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-94M

Kyverna Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Kyverna Therapeutics, Inc.’s (KYTX) StockRank?
MoatMap’s StockRank for Kyverna Therapeutics, Inc. (KYTX) is 25/100, with a Sell signal. It is a composite of Quality (28), Value (37), and Momentum (47) factor ranks across MoatMap’s 19,000+ stock universe.
Does Kyverna Therapeutics, Inc. have an economic moat?
Kyverna Therapeutics, Inc. (KYTX) has a Quality factor score of 28/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Kyverna Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Kyverna Therapeutics, Inc. (KYTX) is Sell, based on a StockRank of 25/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Kyverna Therapeutics, Inc. in?
Kyverna Therapeutics, Inc. (KYTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksKYTX deep dive reportAI ChampionsHow we score stocksSense-check another stock